EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement

Aristides Maniatis iD, Wayne Cutfield iD, Mehul Dattani, Cheri Deal, Paulo Ferrez Collett-Solberg, Reiko Horikawa iD, Mohamad Maghnie iD, Bradley S Miller iD, Michel Polak, Lars Sävendahl, Joachim Woelfle

The Journal of Clinical Endocrinology & Metabolism · 17.03.2025 · 110 (4) · e1232-e1240

DOI: 10.1210/clinem/dgae834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 03.12.2024. Verfasst von Aristides Maniatis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rocky Mountain Pediatric Endocrinology, Centennial, CO 80112, USA. Hauptthemen laut MEDLINE: Human Growth Hormone, Growth Disorders, Hormone Replacement Therapy. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Several long-acting growth hormone (LAGH) therapies have recently become available, but guidance on their usage in children with growth hormone (GH) deficiency is limited.

Methods

International experts in pediatric endocrinology were invited to join a consensus group based on their expertise in treating children with daily GH and LAGH. The group comprised 11 experts from 10 countries across the world. Online group meetings were held in February to March 2024 followed by a 1-day in-person meeting in May 2024 to finalize the consensus recommendations. A targeted literature search approach was used to identify and share evidence ahead of the meetings. Formulations considered were limited to those with international populations in phase III pivotal trials and regulatory approvals in multiple countries. Evidence synthesis Topics covered include patient selection and preference, dose adjustment, initiating and switching therapies, administration, adherence and missed doses, practical considerations, and knowledge gaps. LAGH formulations offer a potential advantage over daily GH injections for children with GH deficiency in terms of reduced injection frequency and treatment burden; this may also be associated with improved adherence and treatment outcomes over time. However, data on LAGH in pediatric GH deficiency are mostly limited to clinical trials, and long-term, real-world data are currently lacking.

Conclusion

This article provides an international consensus on the use of LAGH therapy in children with GH deficiency to guide practitioners when considering these new treatment options for their patients. Long-term data are needed to fill current data gaps and allow the creation of comprehensive evidence-based recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneGrowth DisordersHormone Replacement TherapyHumansChildConsensusDelayed-Action PreparationsPractice Guidelines as Topic

Stichwörter der Autor:innen

childrenconsensusgrowth hormone deficiencylong-acting growth hormone therapypatient selection

Substanzen

Human Growth HormoneDelayed-Action Preparations

Autor:innen und Institutionen

  • Rocky Mountain Pediatric Endocrinology, Centennial, CO 80112, USA.
  • Liggins Institute, University of Auckland, Auckland 1142, New Zealand.
  • Genetics and Genomic Medicine Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.
  • Centre de recherche CHU Ste-Justine, Université de Montréal, Montréal H3T 1C5, Canada.
  • Disciplina de Endocrinologia, Departamento de Medicina Interna, Faculdade de Ciências Medicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-170, Brazil.
  • Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo 157-8535, Japan.

ORCID-Profile: Aristides Maniatis, Wayne Cutfield, Reiko Horikawa, Mohamad Maghnie, Bradley S Miller

Förderung

  • Pfizer Ltd

Zitieren

APA

Maniatis, A., Cutfield, W., Dattani, M., Deal, C., Collett-Solberg, P. F., Horikawa, R., Maghnie, M., Miller, B. S., Polak, M., Sävendahl, L., & Woelfle, J. (2025). Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement. The Journal of Clinical Endocrinology & Metabolism, 110(4), e1232-e1240. https://doi.org/10.1210/clinem/dgae834

Vancouver

Maniatis A, Cutfield W, Dattani M, Deal C, Collett-Solberg PF, Horikawa R, et al. Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement. The Journal of Clinical Endocrinology & Metabolism. 2025;110(4):e1232-e1240. doi:10.1210/clinem/dgae834

BibTeX
@article{Maniatis2025,
  author = {Maniatis, Aristides and Cutfield, Wayne and Dattani, Mehul and Deal, Cheri and Collett-Solberg, Paulo Ferrez and Horikawa, Reiko and Maghnie, Mohamad and Miller, Bradley S and Polak, Michel and Sävendahl, Lars and Woelfle, Joachim},
  title = {Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {4},
  pages = {e1232--e1240},
  doi = {10.1210/clinem/dgae834}
}
Kostenlos starten →